Delivery of sPD1 gene by anti-CD133 antibody conjugated microbubbles combined with ultrasound for the treatment of cervical cancer in mice

To explore new therapeutic options for cervical cancer, the inhibitory effect on cervical cancer of targeted CD133-loaded sPD1 gene microbubbles (MBs) combined with low-frequency ultrasound was studied and its mechanism was explored. We prepared microbubbles conjugated with anti-CD133 antibody to deliver the sPD1 gene and determined concentration, particle size, and potentials of MBs. In addition, we verified that CD133 targeted-MBs could specifically bind to U14 cervical cancer cells in vitro. A mouse model of subcutaneous xenograft cervical cancer was established and mice were divided into a control group, an non-targeted micro-bubble group, a CD133-MBs group, an sPD1-MBs group and a CD133/sPD1-MBs group. Compared with the control group, tumor growth was inhibited in each group, with the CD133/sPD1 group showing the strongest inhibitory effect after treatment. The tumor volume and weight inhibition rates in the CD133/sPD1-MBs group were 78.01% and 72.25% respectively, which were statistically different from the other groups (P < 0.05), and HE staining and TUNEL immunofluorescence showed necrosis and apoptosis in tumor tissue. Flow cytometry, lactate dehydrogenase, and indirect immunofluorescence experiments showed that T lymphocytes were activated and a large number of CD8-positive T cells infiltrated the tumor tissue after treatment, with the CD133/sPD1-MBs group showing the most prominent effects (P < 0.05). The combination of ultrasound with anti-CD133 antibody-conjugated microbubbles loaded with the sPD1 gene can inhibit the growth of cervical cancer, sug-gesting that the immunosuppressive microenvironment of the tumor is improved after treatment.

Automated summary

In this study, the inhibitory effect of targeted CD133-loaded sPD1 gene microbubbles (MBs) combined with low-frequency ultrasound on cervical cancer was explored. The researchers prepared microbubbles conjugated with anti-CD133 antibody to deliver the sPD1 gene and determined the characteristics of the MBs. They found that CD133 targeted-MBs could specifically bind to cervical cancer cells in vitro. In a mouse model of subcutaneous cervical cancer, the CD133/sPD1-MBs group showed the strongest inhibitory effect on tumor growth. The combination of ultrasound with CD133-targeted microbubbles loaded with the sPD1 gene can improve the tumor's immunosuppressive microenvironment.